SCHEDULE: RA Capital Maintains 9.9% Stake in Unicycive Therapeutics

RA Capital Management and its affiliates filed an amended Schedule 13G disclosing a 9.9% beneficial ownership stake in Unicycive Therapeutics, Inc. as of March 31, 2026.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. collectively report beneficial ownership of 2,801,082 shares of Unicycive Therapeutics common stock.
• The reported ownership represents 9.9% of the company's outstanding common stock.
• The holdings consist of shares issuable upon the conversion of Series A-3, A-4, and A-5 Convertible Preferred Stock, which are subject to a 9.99% beneficial ownership blocker.
• The reporting persons disclaim status as a group for the purposes of Section 13(d) of the Securities Exchange Act.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory filing confirming existing institutional positions without signaling new strategic shifts or capital market activity.

Positives

• Continued institutional support from a specialized healthcare investment firm.
• Clear disclosure of ownership structure and limitations via beneficial ownership blockers.

Negatives

• Ownership is capped at 9.99% due to contractual conversion blockers, limiting immediate influence or accumulation potential.

Risks

• The investment is subject to a beneficial ownership blocker that prevents conversion of preferred stock if it would result in ownership exceeding 9.99% of outstanding common stock.
• The reporting persons may be deemed beneficial owners of the securities, which could impact future trading flexibility.

Future Outlook

The filing does not provide a forward-looking business outlook for the issuer, as it is a disclosure of beneficial ownership by an institutional investor.

Management Comments

• The reporting persons certify that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that this filing reflects standard institutional reporting requirements for biotech investors. RA Capital remains a significant stakeholder, which is common for venture-backed or growth-stage pharmaceutical companies relying on specialized life sciences capital.

Comparison to Industry Standards

• The 9.9% ownership threshold is a standard ceiling for institutional investors in small-cap biotech to avoid triggering certain regulatory or poison-pill thresholds.
• The use of beneficial ownership blockers is a common practice in private-to-public transition financing for life sciences companies.

Stakeholder Impact

• Shareholders may view the continued presence of RA Capital as a sign of stability and long-term commitment to the company's clinical development programs.

Next Steps

• Continued monitoring of future 13G or 13D filings by RA Capital regarding changes in their position.

Key Dates

Keywords

Unicycive Therapeutics, RA Capital Management, Schedule 13G, Institutional Ownership, Biotech Investment, Convertible Preferred Stock